Company Research Report: Pillar Biosciences Inc.

Company Overview

Name: Pillar Biosciences Inc.
Mission: Pillar Biosciences aims to optimize precision therapies for cancer patients by utilizing highly accurate and sensitive next-generation sequencing (NGS) testing technology for tumor profiling, therapy selection, and recurrence monitoring. Their mission is encapsulated in their theme of "Decision Medicine™."
Founded: Founded by Dr. Gang Song, the specific founding year is not available.
Key People:

• Gang Song: Founder and Executive Chairman

• Zhaohui Wang, Ph.D.: Co-founder and Chief Scientific Officer

• Dan Harma: Chief Commercial Officer

Headquartered: 9 Strathmore Rd., Natick, MA, 01760
Number of Employees: No information is available
Revenue: No information is available
Known For: Pillar Biosciences is known for its next-generation sequencing (NGS) testing solutions, powered by proprietary SLIMamp® and PiVAT® technologies. The company is a leader in Decision Medicine™, focusing on creating highly accurate and sensitive testing technologies that facilitate precision cancer therapies.

Products

IVD Assays

1. FDA - oncoReveal™ CDx Pan-Cancer Solid Tumor IVD Kit:

• Description: A next-generation sequencing-based in vitro diagnostic (IVD) kit using Pillar’s proprietary SLIMamp technology.

• Key Features: Detects single nucleotide variants (SNVs), insertions, and deletions in 22 genes. Cleared by the FDA for use with formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens.

Research-Use-Only (RUO) Panels

1. oncoReveal Solid Tumor Panel
2. oncoReveal Multi-Cancer Panels:

• Variants: CNV and RNA Fusion Panel, V4 with CNV Panel

3. oncoReveal Myeloid Panel
4. oncoReveal Essential MPN Panel
5. oncoReveal BRCA1 & BRCA2 Plus CNV Panel
6. oncoReveal Core LBx Panel
7. oncoReveal Fusion LBx Panel
8. oncoReveal 4 Gene Methylation Panel
9. oncoReveal HRD v2 Panel
10. oncoReveal Nexus 21 Gene Panel
11. oncoReveal Essential LBx Panel

High-Level Description: Each product offers actionable, rapid and reliable testing results for any Next-generation Sequencing (NGS) laboratory, focusing on enabling accurate and specialty testing for robust clinical outcomes.

Recent Developments

• New Product Launches:

• "OncoReveal Nexus" branded assayed used by Memorial Sloan Kettering Cancer Center.

• "oncoReveal™ CDx" received a unique CPT® code from the American Medical Association for FDA approved pan-cancer profiling.

• Recent Features and Enhancements:

• Pillar Biosciences has developed the oncoReveal™ CDx product, which has been approved as a companion diagnostic across several cancers to guide treatment decisions.

• The OncoReveal Nexus assay analyzes 111 total targets across 21 genes for rapid sequencing applications.

• Recent Partnerships and Collaborations:

• Collaboration with renowned institutions like Memorial Sloan Kettering Cancer Center, Duke University Health, and the University of Southern California’s Keck School of Medicine.

• Partnership with Illumina to enhance NGS testing affordability and accessibility.

• Corporate Events:

• Participation and presentation of impactful research data at the 2024 Association for Molecular Pathology Annual Meeting.

This comprehensive report highlights the essential aspects of Pillar Biosciences as a pioneering company in the field of NGS diagnostic technologies, detailing its mission, product offerings, and recent strategic advancements.